Protalix BioTherapeutics Files 8-K: Material Agreement & Exhibits

TL;DR

PLX filed an 8-K for a new material agreement. Check exhibits for details.

AI Summary

On August 22, 2025, Protalix BioTherapeutics, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statements and exhibits. The company, incorporated in Delaware, is involved in biological products and is headquartered in Hackensack, NJ.

Why It Matters

This 8-K filing signals a significant new agreement for Protalix BioTherapeutics, which could impact its financial standing and future operations. Investors should review the details of the agreement and exhibits for potential implications.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the specifics of this filing require further investigation to assess the full impact on Protalix BioTherapeutics.

Key Players & Entities

• Protalix BioTherapeutics, Inc. (company) — Registrant
• August 22, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Hackensack, NJ (location) — Company Headquarters
• 2 University Plaza, Suite 100 (address) — Company Business Address

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common stock, $0.001 par value PLX NYSE American Indicat

Filing Documents

• tm2524070d1_8k.htm (8-K) — 29KB
• tm2524070d1_ex1-1.htm (EX-1.1) — 15KB
• tm2524070d1_ex5-1.htm (EX-5.1) — 11KB
• tm2524070d1_ex5-1img001.jpg (GRAPHIC) — 4KB
• 0001104659-25-081924.txt ( ) — 229KB
• plx-20250822.xsd (EX-101.SCH) — 3KB
• plx-20250822_lab.xml (EX-101.LAB) — 33KB
• plx-20250822_pre.xml (EX-101.PRE) — 22KB
• tm2524070d1_8k_htm.xml (XML) — 4KB

01 Entry

Item 1.01 Entry into a Material Definitive Agreement On August 22, 2025, Protalix BioTherapeutics, Inc., a Delaware corporation (the "Company") entered into a letter agreement (the "Amendment") amending that certain At The Market Offering Agreement, dated as of February 27, 2023, as amended as of March 17, 2025 ("Sales Agreement"), with H.C. Wainwright & Co., LLC, as the Company's sales agent (the "Agent"), pursuant to which the Company may offer and sell from time to time shares of its common stock, $0.001 par value ("Common Stock"), to or through the Agent in an "at-the-market" equity offering program. The Amendment modifies the Sales Agreement to reflect the effectiveness of the Company's new registration statement on Form S-3 (Registration No. 333- 286802). The foregoing description of the Amendment and the Sales Agreement in this Current Report on Form 8-K does not purport to be complete and is qualified by reference to the full text of the Amendment, which is filed as Exhibit 1.1 hereto, to the full text of the Sales Agreement, which was filed as Exhibit 1.1 to our Current Report on Form 8-K dated February 27, 2023, and to the full text of the letter agreement, dated as of March 17, 2025, which was filed as Exhibit 1.1 to our Current Report on Form 8-K dated March 17, 2025, respectively, each incorporated by reference herein. In connection with the filing of the Amendment, the Company is filing as Exhibit 5.1 hereto an opinion of its counsel, Mayer Brown LLP, with respect to the legality of the shares. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any shares of Common Stock, nor shall there be any sale of shares of Common Stock in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

01Financial

Item 9.01Financial Exhibit No. Description 1.1 Letter Agreement, dated August 22, 2025, to the At the Market Offering Agreement, dated February 27, 2023, between the Company and H.C. Wainwright & Co., LLC 5.1 Opinion of Mayer Brown LLP 23.1 Consent of Mayer Brown LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 22, 2025 PROTALIX BIOTHERAPEUTICS, INC. By: /s/ Dror Bashan Name: Dror Bashan Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR